# EDGAR Filing Document

**Accession Number:** 0001611746
**File Stem:** 0001213900-25-062112
**Filing Date:** 2025-7
**Character Count:** 5157
**Document Hash:** 7cdae499a68a7d97a8f1d424801a8e10
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-062112.hdr.sgml**: 20251217

**ACCESSION NUMBER**: 0001213900-25-062112

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250708

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SciSparc Ltd.
- **CENTRAL INDEX KEY:** 0001611746
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-AUTO DEALERS & GASOLINE STATIONS [5500]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 20 RAUL WALLENBERG STREET, TOWER A
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6971916
- **BUSINESS PHONE:** 972-3-6103100

**MAIL ADDRESS:**
- **STREET 1:** 20 RAUL WALLENBERG STREET, TOWER A
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6971916

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SciSparc Ltd./ADR
- **DATE OF NAME CHANGE:** 20210129

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Therapix Biosciences Ltd.
- **DATE OF NAME CHANGE:** 20140624

July 8, 2025

***VIA EDGAR***

United States Securities and Exchange Commission<br> Division of Corporation Finance<br> 100 F Street, N.E.

Washington, D.C. 20549-6010

---

| | | |
|:---|:---|:---|
| Attention: | Valeria Franks | Valeria Franks |
|  | Suying Li | Suying Li |
|  | Cara Wirth | Cara Wirth |
|  | Donald Field | Donald Field |
|  | **Re:** | **SciSparc Ltd.** |
|  |  | **Amendment No. 8 to Registration Statement on Form F-4** |
|  |  | **Filed on June 25, 2025** |
|  |  | **File No. 333-282351** |

---

Ladies and Gentlemen:

On behalf of SciSparc Ltd. (the "***Company***" or "***SciSparc***"), we submit this letter setting forth the responses of the Company to the comment provided by the staff (the "***Staff***") of the Securities and Exchange Commission (the "***Commission***") in its comment letter dated July 7, 2025 (the "***Comment Letter***"), with respect to Amendment No. 8 to Registration Statement on Form F-4 filed with the Commission by the Company on June 25, 2025 (the "***Registration Statement***"). Concurrently with the filing of this letter, the Company is hereby filing Amendment No. 9 to the Registration Statement (the "***Amended Filing***") through EDGAR.

For reference purposes, the text of the Comment Letter has been reproduced herein with responses below to the numbered comment. Unless otherwise indicated, page references in the description of the Staff's comment refer to the Registration Statement and page references in the response refer to the Amended Filing. Unless otherwise indicated, capitalized terms herein have the meanings assigned to them in the Amended Filing.

***Amendment No. 8 to Registration Statement on Form F-4 filed June 25, 2025***

***Consolidated Financial Statements, page F-1***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.** **Your disclosure in the filing indicates that you expect to effect a one-for-twenty one reverse share split prior to the completion of the merger. Please provide clarification as to when your anticipated reverse share split will be effected in relation to the effectiveness of this registration statement. Please also tell us how you anticipate reflecting the reverse share split retrospectively in your historical financial statements. Refer to the guidance in paragraphs 26 through 29 and 64 of IAS 33 and SAB Topic 4.C.** 

*Response:* The Company respectfully acknowledges the Staff's comment, and notes that it has effected a one-for-twenty-one reverse share split, effective as of market open on July 3, 2025 (the "**Reverse Split**"). The Company has revised the section titled "About This Document", page vii, and throughout the Amended Filing to provide an update on the effectiveness of the Reverse Split. The Company has revised its unaudited pro forma condensed combined financial statements to reflect the effectiveness of the Reverse Split. The Company has also revised its historical financial statements to reflect share numbers, prices and exercise prices to reflect the Reverse Split. In addition, the Company has revised the basic and diluted loss per share, and the weighted average outstanding shares (basic and diluted) in the consolidated statement of comprehensive loss, to reflect the Reverse Split. The Company revised page F-11 to add note 1(d), which clarifies that share and per share information in the financial statements of the Company has been retroactively adjusted to reflect the Reverse Split for all periods presented.

\* \* \*

We hope the foregoing answers are responsive to your comments. Please do not hesitate to contact me by telephone at +972-50-552-1058 with any questions or comments regarding this correspondence.

---

| |
|:---|
| Very truly yours, |
| /s/ Oz Adler |
| Oz Adler |
| Chief Executive Officer |
| SCISPARC LTD. |

---

---

| | |
|:---|:---|
| cc: |  |
|  | Shachar Hadar, Meitar \| Law Offices |
|  | Matthew Rudolph, Meitar \| Law Offices |
|  | Oded Har-Even, Sullivan & Worcester LLP |
|  | Howard Berkenblit, Sullivan & Worcester LLP |

---